|
Diabetes
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Despite the emerging consensus on the role of ZnT8 in glucose homeostasis, a recent genetic study in humans has unexpectedly identified loss-of-function SLC30A8 mutants that are associated with protection from diabetes.
|
25287711 |
2015 |
|
Diabetes
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Moreover, overexpression of human ZnT8 diabetes high-risk allele R325W increased 5-HT levels relative to the low-risk allele in RIN14B cells.
|
30936149 |
2019 |
|
Diabetes
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The C-terminal cytosolic domain of the human zinc transporter ZnT8 and its diabetes risk variant.
|
29430817 |
2018 |
|
Diabetes
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We assessed diabetes risk associated with zinc transporter-8 antibodies (ZnT8A), islet cell antibodies (ICA), and HLA type and age in relatives of people with type 1 diabetes with the standard biochemical autoantibodies (BAA) to insulin (IAA), GAD65 (GAD65A), and/or insulinoma-associated protein 2 antigen (IA-2A).
|
22446173 |
2012 |
|
Diabetes
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Associations between ZnT8 antibody (ZnT8A), phenotype and the genetic variant rs13266634 in the SLC30A8 gene have primarily been studied in patients with young-onset diabetes.
|
23061550 |
2013 |
|
Diabetes
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The dependence on ZnT8 of hypoxia-induced changes in cell survival may contribute to the actions of SLC30A8 variants on diabetes risk in humans.
|
24865615 |
2014 |
|
Diabetes
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In this review, we summarize the structure, feature, functions, and polymorphisms of ZnT8 along with its association with diabetes and explore future study directions.
|
30936916 |
2019 |
|
Diabetes
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Genome-wide association studies have previously identified variants in SLC30A8, encoding the zinc transporter ZnT8, associated with diabetes risk.
|
24675520 |
2014 |
|
Diabetes
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The majority of multiple-autoAb<sup>+</sup> individuals progress to diabetes within 20 years; this occurs more rapidly in the presence of IA-2A or ZnT8A, regardless of age, <i>HLA-DQ</i> genotype, and number of autoAbs.
|
28701370 |
2017 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
A total of 31 Somali children ≤19 yr were treated for type 1 diabetes (T1D) at the University of Minnesota Masonic Children's Hospital and Children's Hospitals and Clinics of Minnesota underwent analysis of human leukocyte antigen (HLA) alleles (n = 30) and diabetes autoantibodies [glutamic acid decarboxylase (GAD65), islet antigen 2 (IA-2), zinc transporter 8 (ZnT8); n = 31].
|
26854192 |
2017 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here we characterize an emerging role of ZnT-8 in diabetes and discuss potential mechanisms of its involvement in the etiology of both forms of diabetes.
|
19655390 |
2009 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
The Diabetes Susceptibility Gene SLC30A8 that Encodes the Zinc Transporter ZnT8 is a Pseudogene in Guinea Pigs Potentially Contributing to Low Guinea Pig Islet Zinc Content.
|
30392157 |
2018 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Blood samples were obtained from 900 patients with age from 1 month to 25 years (median age 11.1 years) within 2 weeks of diabetes onset to test anti-islet autoantibodies to insulin (IAA), glutamic acid decarboxylase (GADA), insulinoma antigen (IA-2AA), the zinc transporter-8 (ZnT8AA), and islet-cell antibodies (ICA).
|
21138544 |
2011 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
A total of 97 subjects with diabetes onset before age 25, a random C-peptide ≥0.1 ng/mL, and negative for all diabetes autoantibodies (GADA, IA-2, ZnT8, and IAA) were enrolled, after excluding 21 subjects with secondary diabetes or refusal to participate.
|
26059258 |
2016 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
The use of GADAs, IA-2As, and ZnT8As in combination allowed a stratification of clinical phenotype, with younger age of onset of diabetes and characteristics of more severe insulin deficiency (higher fasting glucose and A1C, lower BMI, total cholesterol, and triglycerides) in patients with all three markers, with progressive attenuation in patients with two, one, and no antibodies (all P(trend) < 0.001).
|
19808923 |
2010 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Children, younger than 15 years of age (n = 723) who were newly diagnosed with diabetes, were analyzed for ZnT8A, other diabetes-associated autoantibodies, HLA DR-DQ alleles, and metabolic status, which was monitored by pH, plasma glucose, and occurrence of ketoacidosis at diagnosis and through follow-up of C-peptide concentrations, exogenous insulin dose, and glycosylated hemoglobin for 2 years after the diagnosis.
|
26519333 |
2016 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
ZnT8-ab are associated with more acute diabetes onset.
|
29327148 |
2018 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
ZnT8-ab positive patients had higher titre and more frequent occurrence of multiple diabetes-related autoantibodies than ZnT8-ab negative patients.
|
30465779 |
2018 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Prevalence of diabetes and presence of autoantibodies against zinc transporter 8 and glutamic decarboxylase at diagnosis and at follow up of Graves' disease.
|
30783963 |
2019 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
It argues against ZnT8 autoimmunity arising from molecular mimicry and suggests a mechanistic link between the two major forms of diabetes.
|
18591387 |
2008 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Moreover, Znt8 Arg-325 risk variant shows an enhanced inflammatory response upon LPS stimulation that might aggravate insulin resistance and the progression of diabetes cardiovascular complications.
|
30142362 |
2018 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Other outcomes are: (1) Any persistent confirmed beta-cell autoantibody (glutamic acid decarboxylase (GADA), IA-2A, autoantibodies to insulin (IAA) and zinc transporter 8 or tetraspanin 7), or diabetes, (2) Persistent confirmed IAA, (3) Persistent confirmed GADA and (4) Abnormal glucose tolerance or diabetes.
|
31256036 |
2019 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
In the present review, we summarize the literature about clinical aspects of ZnT8 in the pathogenesis of diabetes, and suggest that ZnT8 might play a different role between type 1 diabetes mellitus and type 2 diabetes mellitus.
|
27181765 |
2016 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
A registry-based group of 288 persistently autoantibody-positive (Ab(+)) offspring/siblings (aged 0-39 years) of known patients (Ab(+) against insulin, GAD, IA-2 and/or ZnT8) were typed for HLA-DQ, -A and -B and monitored from the first Ab(+) sample for development of diabetes within 5 years.
|
23712485 |
2013 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
ZnT8 was therefore proposed as a therapeutic target for diabetes, and recent genome-wide association studies identified polymorphisms in the ZNT8 gene conferring increased type 2 diabetes risk.
|
19095428 |
2009 |